Nivorz (nivolumab biosimilar) / Dr. Reddy’s - LARVOL DELTA

Pharma major Dr Reddy’s Laboratories on Tuesday announced its foray into the Indian biosimilar immuno-oncology market with the rollout of its biosimilar version of Bristol Myers Squibb’s Opdivo (nivolumab). (The Times of India) - "The drug has been approved for use in lung, kidney, head and neck, melanoma, lymphoma, urothelial, colorectal, gastric, oesophageal, mesothelioma and liver cancers in India."

Biosimilar launch • Classical Hodgkin Lymphoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Malignant Pleural Mesothelioma • Melanoma • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer